On July 30, 2024, BioNTech SE reported positive topline data from a Phase 2 clinical trial for its mRNA immunotherapy candidate BNT111, targeting advanced melanoma patients who progressed after previous treatment.
AI Assistant
BIONTECH SE
2024
6 K
Find Answers
Ask about any part of the document to get insights, explanations, or key details.